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2Peptide Therapeutics Constitutes an Unique Modality
Small molecule drugs
< 500 Da
Biologics > 5000 Da 
(e.g. cytokines, growth 
factors, mAbs)
Injectable
Peptides
5 ~ 40 
amino acids
Chemical control and definition
Dosing route
Specificity and half-life
Liraglutide
• Peptide products differentiate with other modalities in targets requiring high 
affinity agonist action, especially those associated with natural hormones.  
3• Formulation goal: bioavailability + stability + sterility…
• Peptides typically don’t have well ordered structure and therefore chemical and physical stability 
could be worse than biologics. Daily use product require >18 month 5⁰C solution product
• In particular, poor understanding in the developability study for physical stability
• Stability could frequently be the limiting factors in peptide formulation development (e.g. glucagon).
Peptides Present Unique Challenges for Parenteral 
Formulation Development
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4Reversible and Irreversible Aggregation 
in Synthetic Peptides 
4
Oligomers
Nonspecific 
reversible
aggregates
Prefibrillar 
species Irreversible
fibrils
Native conformation
β-sheet conformation
Monomer
Variable conformation 
(T, pH, ion, etc)
Disordered 
irreversible
aggregates
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5
Amyloid Fibrils are Supramolecular Assemblies with 
Highly Ordered Stacking 
Science. 2017 Oct 6;358(6359):116-119
6Nucleated Polymerization of Fibril Kinetics
7Where is the Gap in the Development Knowledge?
• Is it because the how representative the materials are (both 
benchmarks and peptide A)?  
• Is it due to the non-ideal behavior in kinetics between accelerated 
conditions and real time?
• Purity
• Manufacturing method
• Counterions
• Preexisting seeds
• ….
High unfolding energy 
can contribute to the 
non-Arrhenius behavior.
N
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40⁰C 5⁰C
k=A*exp(-Ea/R*T) 
8Small Peptides are Conformationally Unstable—Unlike 
Most Proteins
• Unfolding is of low cooperativity and reversible. 
• Helical peptides undergo gradual melting upon heating 
Formulation 
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Tm (C) ΔHm
(kcal/mol)
ΔSm
(cal/mol/K)
ΔG20 C 
(kcal/mol)
pH 6 74.9  1.9 47.7  14.1 137.2  40.5 7.5
pH 7 75.2  2.4 21.2  4.9 60.9  14.0 3.3
pH 8 65.2  0.7 26.2  3.9 77.4  11.4 3.5
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Mw 3.8 kDa, 
29 residues
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Accelerated Study Conditions: Assembly of Peptide 
Alone Shows Arrhenius Kinetics
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Assembly of Peptide Alone Shows Arrhenius 
Kinetics: Accelerated vs. Real Time 
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• Peptide alone demonstrates an aggregation kinetics that 
are Arrhenius in nature. i.e accelerated testing at high T 
and shear could be used to extrapolate to real time.
• Temperature behavior in kinetics cannot explain the 
observed effects.
Can “Seeds” Play a Role in the Kinetics?
• Is it because the how representative the materials are (both 
benchmarks and peptide 2)?  
• Purity
• Manufacturing method
• counterions
• Preexisting seeds
• ….
12
How can Submicron “Seed” Species Influence Product 
Quality? Can We Detect Them Quantitatively?
5 nm (60%)
130 nm
2 µm
• “nucleated polymerization and growth”  
• Submicron species appear to serve as 
nucleus to physical instability
• Will API history influence DP 
performance?
13
• Conventional aggregation control method did not work for 
these purpose.
• Use of the ThioT kinetic test (i.e, assume the lag time 
correlate with presence of amount of seeds)
• Can we leverage the use of submicron tools, although 
may need to differentiate between active vs inactive 
seeds.
Methods explored for detecting of the “seeds”
14
• Peptides are uniquely differentiated from protein and small molecules.
• Aggregation is a significant risk for pharmaceutical development of peptide 
drug products. Understanding of aggregation pathway is highly important to its 
development.
• Fibrillation kinetics are highly sensitive to its preparation method, purity, 
existing of seeds etc. Seamless integration between DS and DP are required. 
Conclusion
Reversible Irreversible
Small reversible aggregates
(dimer, trimer, tetramer, etc)
Covalent aggregates
Irreversible noncovalent aggregates
“Large” aggregates (could be reversible)Monomer
Fibrils, micelles, and more
Soluble and insoluble
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